ONLY FOR SOUTH AFRICAN RESIDENTS
S1 TELFAST® SUSPENSION. Each 1 ml contains 6 mg fexofenadine hydrochloride. Reg. No. 42/5.7.1/0339. For full prescribing information refer to professional information approved by the medicines regulatory authority.
S1 TELFAST® 120. Each tablet contains 120 mg fexofenadine hydrochloride per tablet. Reg. No.: 32/5.7.1/0446. For full prescribing information refer to professional information approved by the medicines regulatory authority.
S1 TELFAST® 180. Each tablet contains 180 mg fexofenadine hydrochloride per tablet. Reg. No.: 32/5.7.1/0447.
For full prescribing information refer to Professional Information approved by the medicines Regulatory
Authority.
Applicant: Opella Healthcare South Africa (Pty) Ltd, Reg. no.: 2020/176440/07.
4th Floor, Building I, Hertford
Office Park, 90 Bekker Road, Midrand, 1652.
www.sanofi.co.za
Side Effects / Safety:
za.CHCdrugsafety@sanofi.com
Medical Queries:
za.chcenquiries@sanofi.com
Product Quality Complaints:
CHC-ZAQAComplaints@sanofi.com
Side Effects / Safety:
za.Drugsafety@sanofi.com
Medical Queries:
za.CHCenquiries@sanofi.com
Product Quality Complaints:
za.productqualitycomplaints@sanofi.com
Sanofi Regional Office, Jumeirah Lakes Towers, Dubai, UAE.
To report adverse events, please call: +971561747001
Or email:
gulf.pharmacovigilance@sanofi.com.
Personal health questions must be discussed with healthcare professionals.
You should consult a physician or pharmacist before using a medicinal product. With best
wishes from Ministry of Health and Prevention.
